- Capital Cube•2 months ago
Click here to see latest analysisÆterna Zentaris, Inc. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Æterna Zentaris, Inc. – Spectrum Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Novartis AG Sponsored ADR, Sanofi Sponsored ADR, Bristol-Myers Squibb Company and Halozyme Therapeutics, Inc. (SPPI-US, KERX-US, NVS-US, SNY-US, […] (Read more...) The post Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 appeared first on CapitalCube.
- Associated Press•3 months ago
On a per-share basis, the Montreal-based company said it had a loss of 37 cents. The drug developer posted revenue of $242,000 in the period. In the final minutes of trading on Monday, the company's shares ...
|Bid||3.06 x 500|
|Ask||4.00 x 3000|
|52wk Range||2.60 - 20.00|
|Day's Range||3.31 - 3.40|
|Avg Vol (3m)||200,471|
As of 4:00 PM EDT. Market closed.